Salivary biomarkers for diagnosis of systemic diseases and malignant tumors. A systematic review.
Journal
Medicina oral, patologia oral y cirugia bucal
ISSN: 1698-6946
Titre abrégé: Med Oral Patol Oral Cir Bucal
Pays: Spain
ID NLM: 101231694
Informations de publication
Date de publication:
01 Mar 2020
01 Mar 2020
Historique:
received:
28
07
2019
accepted:
06
08
2019
pubmed:
11
2
2020
medline:
29
2
2020
entrez:
11
2
2020
Statut:
epublish
Résumé
Saliva evaluation could be a possible alternative to blood and/or tissue analyses, for researching specific molecules associated to the presence of systemic diseases and malignancies. The present systematic review has been designed in order to answer to the question "are there significant associations between specific salivary biomarkers and diagnosis of systemic diseases or malignancies?". The Preferred Reporting Item for Systematic Reviews and Meta-analysis (PRISMA) statement was used to guide the review. The combinations of "saliva" and "systemic diseases" or "diagnosis" or "biomarkers" or "cancers" or "carcinoma" or "tumors", were used to search Medline, Scopus and Web of Science databases. Endpoint of research has been set at May 2019. Studies were classified into 3 groups according to the type of disease investigated for diagnosis: 1) malignant tumors; 2) neurologic diseases and 3) inflammatory/metabolic/cardiovascular diseases. Assessment of quality has been assigned according to a series of questions proposed by the National Institute of Health. Level of evidence was assessed using the categories proposed in the Oxford Center for Evidence-Based medicine (CEMB) levels for diagnosis (2011). Seventy-nine studies met the inclusion and exclusion criteria. Fifty-one (64%) investigated malignant tumors, 14 (17.5%) neurologic and 14 (18.5%) inflammatory/cardiovascular/metabolic diseases. Among studies investigating malignant tumors, 12 (23.5%) were scored as "good" and 11 of these reported statistically significant associations between salivary molecules and pathology. Two and 5 studies were found to have a good quality, among those evaluating the association between salivary biomarkers and neurologic and inflammatory/metabolic/cardiovascular diseases, respectively. The present systematic review confirms the existence of some "good" quality evidence to support the role of peculiar salivary biomarkers for diagnosis of systemic diseases (e.g. lung cancer and EGFR).
Sections du résumé
BACKGROUND
BACKGROUND
Saliva evaluation could be a possible alternative to blood and/or tissue analyses, for researching specific molecules associated to the presence of systemic diseases and malignancies. The present systematic review has been designed in order to answer to the question "are there significant associations between specific salivary biomarkers and diagnosis of systemic diseases or malignancies?".
MATERIALS AND METHODS
METHODS
The Preferred Reporting Item for Systematic Reviews and Meta-analysis (PRISMA) statement was used to guide the review. The combinations of "saliva" and "systemic diseases" or "diagnosis" or "biomarkers" or "cancers" or "carcinoma" or "tumors", were used to search Medline, Scopus and Web of Science databases. Endpoint of research has been set at May 2019. Studies were classified into 3 groups according to the type of disease investigated for diagnosis: 1) malignant tumors; 2) neurologic diseases and 3) inflammatory/metabolic/cardiovascular diseases. Assessment of quality has been assigned according to a series of questions proposed by the National Institute of Health. Level of evidence was assessed using the categories proposed in the Oxford Center for Evidence-Based medicine (CEMB) levels for diagnosis (2011).
RESULTS
RESULTS
Seventy-nine studies met the inclusion and exclusion criteria. Fifty-one (64%) investigated malignant tumors, 14 (17.5%) neurologic and 14 (18.5%) inflammatory/cardiovascular/metabolic diseases. Among studies investigating malignant tumors, 12 (23.5%) were scored as "good" and 11 of these reported statistically significant associations between salivary molecules and pathology. Two and 5 studies were found to have a good quality, among those evaluating the association between salivary biomarkers and neurologic and inflammatory/metabolic/cardiovascular diseases, respectively.
CONCLUSIONS
CONCLUSIONS
The present systematic review confirms the existence of some "good" quality evidence to support the role of peculiar salivary biomarkers for diagnosis of systemic diseases (e.g. lung cancer and EGFR).
Identifiants
pubmed: 32040469
pii: 23355
doi: 10.4317/medoral.23355
pmc: PMC7103445
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e299-e310Références
J Oral Biol Craniofac Res. 2016 Jan-Apr;6(1):66-75
pubmed: 26937373
Oral Dis. 2011 Sep;17(6):597-600
pubmed: 21635668
Cancer Invest. 2000;18(2):101-9
pubmed: 10705871
J Oral Pathol Med. 2006 May;35(5):292-300
pubmed: 16630293
Oral Dis. 2013 Mar;19(2):180-4
pubmed: 22834943
Exp Biol Med (Maywood). 2017 Mar;242(5):459-472
pubmed: 27903834
Am J Respir Crit Care Med. 2014 Nov 15;190(10):1117-26
pubmed: 25317990
PLoS One. 2010 Dec 31;5(12):e15573
pubmed: 21217834
Asian Pac J Cancer Prev. 2016;17(1):335-9
pubmed: 26838233
J Contemp Dent Pract. 2011 Mar 01;12(2):114-9
pubmed: 22186754
Int J Biol Macromol. 2018 Mar;108:503-514
pubmed: 29222021
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Med Oral Patol Oral Cir Bucal. 2009 Oct 01;14(10):e521-4
pubmed: 19680209
EBioMedicine. 2018 Jul;33:57-67
pubmed: 30045829
Eur Urol. 2000 Nov;38(5):550-4
pubmed: 11096235
Neurobiol Aging. 2018 Oct;70:125-127
pubmed: 30007161
Gastroenterology. 2010 Mar;138(3):949-57.e1-7
pubmed: 19931263
Adv Dent Res. 2005 Jun;18(1):17-24
pubmed: 15998939
J Proteome Res. 2009 Jan;8(1):239-45
pubmed: 19118452
Anal Bioanal Chem. 2015 Sep;407(23):7189-96
pubmed: 26168969
Spec Care Dentist. 2019 Jan;39(1):39-44
pubmed: 30536408
J Forensic Leg Med. 2014 Feb;22:45-50
pubmed: 24485421
Cancer Invest. 2015;33(10):510-5
pubmed: 26506284
Pathol Res Pract. 2017 Apr;213(4):394-399
pubmed: 28283209
Anal Chim Acta. 2017 Aug 22;982:84-95
pubmed: 28734369
Neurosci Lett. 2019 Mar 23;696:114-120
pubmed: 30579996
J Alzheimers Dis. 2019;68(2):583-589
pubmed: 30814361
World J Gastroenterol. 2009 Feb 21;15(7):865-70
pubmed: 19230049
J Ovarian Res. 2018 Jul 24;11(1):61
pubmed: 30041680
Indian J Med Res. 2013 Dec;138(6):861-5
pubmed: 24521627
J Periodontol. 2011 May;82(5):716-25
pubmed: 21091346
Stat Med. 2004 Jun 30;23(12):1921-86
pubmed: 15195324
Brain. 2010 Mar;133(Pt 3):713-26
pubmed: 20157014
Oncol Rep. 2016 Oct;36(4):2375-81
pubmed: 27573701
Am J Dent. 2009 Aug;22(4):241-8
pubmed: 19824562
Clin Chem. 2018 Oct;64(10):1513-1521
pubmed: 30097497
Clin Chim Acta. 2015 Jul 20;447:23-31
pubmed: 25987308
Anal Bioanal Chem. 2018 Jul;410(18):4459-4468
pubmed: 29732495
Sci Rep. 2016 Feb 25;6:22165
pubmed: 26911362
Mol Cell Proteomics. 2012 Feb;11(2):M111.012112
pubmed: 22096114
Mol Med Rep. 2008 May-Jun;1(3):375-8
pubmed: 19844594
Arch Oral Biol. 2009 Jan;54(1):86-90
pubmed: 18817906
Anal Chem. 2013 Dec 17;85(24):11835-42
pubmed: 24274257
Lancet. 2010 Sep 25;376(9746):1094-108
pubmed: 20870100
Pathol Oncol Res. 2013 Jul;19(3):509-13
pubmed: 23479082
N Am J Med Sci. 2014 Dec;6(12):633-7
pubmed: 25599051
Clin Chem. 2009 Aug;55(8):1530-8
pubmed: 19556448
J Proteomics. 2018 Sep 15;187:212-222
pubmed: 30086402
PLoS One. 2015 Jun 29;10(6):e0130996
pubmed: 26121640
Oncotarget. 2017 May 30;8(22):35718-35727
pubmed: 28415698
Annu Rev Biomed Eng. 2008;10:107-44
pubmed: 18358075
J Int Med Res. 2018 Sep;46(9):3570-3582
pubmed: 29916282
Scand J Gastroenterol. 2012 Oct;47(10):1234-41
pubmed: 22871105
J Alzheimers Dis. 2017;58(2):355-359
pubmed: 28453477
J Evid Based Dent Pract. 2015 Dec;15(4):164-70
pubmed: 26698002
Int J Nanomedicine. 2015 Jan 12;10:537-47
pubmed: 25609959
Mol Ecol Resour. 2009 Jan;9(1):51-60
pubmed: 21564566
Front Public Health. 2017 Apr 11;5:77
pubmed: 28443278
Thorac Cancer. 2016 Jul;7(4):428-36
pubmed: 27385985
Electrophoresis. 2013 Oct;34(19):2865-72
pubmed: 23857558
Oncotarget. 2016 May 3;7(18):25408-19
pubmed: 27028998
J Biomed Opt. 2012 Mar;17(3):037003
pubmed: 22502575
Cancer Biomark. 2018;22(4):669-681
pubmed: 29865036
J Biomed Nanotechnol. 2018 Oct 1;14(10):1773-1784
pubmed: 30041723
Oncol Rep. 2018 May;39(5):2217-2224
pubmed: 29498406
Sci Rep. 2017 Apr 11;7(1):796
pubmed: 28400582
J Mol Med (Berl). 2012 Apr;90(4):427-34
pubmed: 22095100
Parkinsonism Relat Disord. 2015 Oct;21(10):1251-5
pubmed: 26231472
Talanta. 2016 Sep 1;158:351-360
pubmed: 27343615
Mov Disord. 2018 Apr;33(4):583-591
pubmed: 29488275
J Transl Med. 2014 Nov 19;12:321
pubmed: 25407125
World J Gastroenterol. 2018 Nov 21;24(43):4846-4861
pubmed: 30487695
Parkinsonism Relat Disord. 2019 Jun;63:143-148
pubmed: 30796010
Clin Oral Investig. 2012 Jun;16(3):775-9
pubmed: 21681388
Front Oncol. 2018 Nov 20;8:520
pubmed: 30524957
Hum Pathol. 2015 Oct;46(10):1540-7
pubmed: 26255234
Cancer Prev Res (Phila). 2015 Feb;8(2):165-73
pubmed: 25538087
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Proteomics Clin Appl. 2010 Mar;4(3):315-24
pubmed: 21137052
Brain. 2011 Jul;134(Pt 7):e178
pubmed: 21349902
Cell Mol Life Sci. 2012 Oct;69(19):3341-3350
pubmed: 22689099
Glycobiology. 2019 Mar 1;29(3):242-259
pubmed: 30535277
J Transl Med. 2016 Sep 08;14:262
pubmed: 27608975
Am J Cancer Res. 2015 Sep 15;5(10):3111-22
pubmed: 26693063
Am Fam Physician. 2004 Mar 1;69(5):1133-40
pubmed: 15023013
Clin Chim Acta. 2016 Jan 15;452:18-26
pubmed: 26523874
Metabolomics. 2010 Mar;6(1):78-95
pubmed: 20300169
Onco Targets Ther. 2014 Jul 14;7:1285-9
pubmed: 25053886
PeerJ. 2015 Nov 05;3:e1373
pubmed: 26587342